The optimal integration of systemic therapy and comprehensive local treatment in non-oncogene-addicted de novo oligometastatic non-small cell lung cancer (NSCLC) remains uncertain. We retrospectively analysed a nationwide cohort of 107 patients with synchronous or metachronous de novo oligometastatic NSCLC treated at a single national referral centre between 2018 and 2022. All oligometastatic lesions received stereotactic body radiotherapy or stereotactic radiosurgery, while the primary tumour was definitively treated where applicable. Median follow-up was 65.2 months, median overall survival (OS) 22.6 months, and median progression-free survival (PFS) 10.1 months. On multivariable analysis, immunotherapy-based systemic treatment was associated with improved PFS versus chemotherapy-based treatment (adjusted hazard ratio [aHR] 0.46, 95% CI 0.22–0.96; p=0.038). Conventional radiotherapy ± chemotherapy to the primary tumour, compared with surgery or SBRT, was associated with worse OS (aHR 2.00, 95% CI 1.22–3.27; p=0.006) and PFS (aHR 1.99, 95% CI 1.23–3.20; p=0.005). Metastatic-lesion BED₁₀ ≥60 Gy was associated with improved PFS (aHR 0.54, 95% CI 0.34–0.84; p=0.006). These findings support further investigation of integrated systemic and comprehensive local treatment strategies in this population.